TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Public ClinicalTrials.gov record NCT04887506. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3 Study Investigating the Efficacy and Safety of TAVT-45 (Abiraterone Acetate) Granules for Oral Suspension (Novel Abiraterone Acetate Formulation) Relative to a Reference Abiraterone Acetate Formulation in Patients With mCSPC & mCRPC
Study identification
- NCT ID
- NCT04887506
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Tavanta Therapeutics
- Industry
- Enrollment
- 107 participants
Conditions and interventions
Conditions
Interventions
- Prednisone Drug
- TAVT-45 Drug
- Zytiga Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 4, 2021
- Primary completion
- Oct 19, 2022
- Completion
- Oct 19, 2022
- Last update posted
- Jan 15, 2024
2021 – 2022
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Homewood | Alabama | 35209 | — |
| Research Site | Tucson | Arizona | 85715 | — |
| Research Site | Little Rock | Arkansas | 72211 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | San Bernardino | California | 92404 | — |
| Research Site | Denver | Colorado | 80211 | — |
| Research Site | Bradenton | Florida | 34205 | — |
| Research Site | Meridian | Idaho | 83642 | — |
| Research Site | Jeffersonville | Indiana | 47130 | — |
| Research Site | Annapolis | Maryland | 21401 | — |
| Research Site | Troy | Michigan | 48084 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Virginia Beach | Virginia | 23462 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 29 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04887506, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2024 · Synced Apr 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04887506 live on ClinicalTrials.gov.